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A 37 amino acid-peptide has been isolated from porcine jejuno-ileum on the basis of its glucagon-like 
activity in liver (interaction with glucagon-binding sites and activation of adenylate cyclase) using gel fil- 
tration, ion-exchange and high-performance liquid chromatography. Depending on the criteria chosen, 
this peptide is referred to as either 'bioactive nteroglucagon' (activity in liver), 'oxyntomodulin' (specific 
action in gastric oxyntic glands) or 'glucagon-37' (chemical structure). 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
The presence of glucagon-like material in intes- 
tine has been long known, owing to its interaction 
with glucagon-sensitive biological [1] and immu- 
nological [2] systems. Using in vitro models, we 
have shown that a porcine intestinal peptide that 
displays glucagon-like immunoreactivity was able 
to interact with the glucagon-receptors and to acti- 
vate the adenylate cyclase present in liver mem- 
branes [3,4]. We have used these criteria for fol- 
lowing up the different steps of purification of the 
peptide responsible for those activities. This paper 
describes the isolation procedure of the peptide 
which is referred to as 'bioactive nteroglucagon' 
because of its glucagon-like ffect in liver, or 
'oxyntomodulin' owing to its specific action on the 
acid-secreting gastric area [5]. The term 'glucagon- 
37' refers to its chemical structure, described in [6]. 
* To whom correspondence should be directed at new 
address: Centre de Pharmacologie-Endocrinologie 
CNRS/INSERM, B.P. 5055, 34033 Montpellier, 
France 
2.1. Study of the binding of leSI-glucagon to rat 
liver plasma membranes 
Rat liver plasma membranes were prepared ac- 
cording to step 11 in [7]. Porcine pancreatic 
glucagon was labeled with Na125I at -0.4 iodine 
atoms/molecule according to a modification [4] of 
the chloramine T procedure [8]. Binding studies 
were done as in [4]. 
2.2. Study of the adenylate cyclase activity 
Adenylate cyclase activity and its stimulation by 
the different fractions were measured in rat liver 
plasma membranes as in [4] using a radioimmuno- 
assay procedure for cyclic AMP [9]. 
2.3. Extraction procedures 
Porcine intestines were extracted by the methods 
used for the isolation of several gastro-intestinal 
peptides [10]. The procedure includes a heat-co- 
agulation of the bulk of the proteins, an extraction 
of polypeptides with 0.5 M CH3COOH, adsorption 
on alginic acid, elution with 0.2 M HCI and pre- 
cipitation with NaC1 at saturation (see section 3). 
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2.4. Gel filtration procedures 
Sephadex G-25 gels (fine or coarse; Pharmacia, 
Uppsala) were prepared and packed in commer- 
cially available glass columns using the technique 
in [11]. Bio-Gel P6 100-200 mesh (Bio-Rad, CA) 
was prepared and packed according to the man- 
ufacturer. All gel filtrations were performed with 
0.2 M CH3COOH as the eluent and monitored by 
UV absorbance at 280 nm using Zeiss or Gilford 
instruments. The fractions were pooled and lyoph- 
ilized (see figure legends). 
2.5. Ion-exchange chromatography 
CM-Sepharose (Pharmacia) was prepared ac- 
cording to the manufacturer. The chromatography 
was run in 22.5 mM pyrophosphate buffer (pH 
6.5) containing 5% dimethylformamide and eluted 
with a linear gradient generated by a peristaltic 
pump (P3, Pharmacia) of 0-0.3 M NaC1 in the 
same buffer at constant pH. The fractions were 
pooled, desalted by gel filtration on a Sephadex 
G-25 (coarse) 2.5 x 100 cm column eluted with 
0.2 M CH3COOH, and lyophilized. 
2.6. High-performance liquid chromatography 
(HPLC) 
The apparatus consisted of two model 6000 A 
solvent delivery systems controlled by a model 660 
solvent programmer, a U6K injector, a model 440 
UV detector operated at 280 nm and a model 450 
variable wavelength detector (operated at 220 or 
215 nm). These instruments were from Waters As- 
soc. (France). Peak heights and peak areas were 
calculated by a SP 4100 computing integrator 
(Spectra Physics, USA). The column (Zorbax ODS 
0.46 × 25 cm, Du Pont de Nemours, USA)-sol- 
vent system (1% CF3COOH buffered with diethyl- 
amine at pH 2.5) was that in [12]. The column used 
for desalting (~ Bondapak CN 0.4 x 30 cm) was 
from Waters Assoc. 
2.7. Flat bed isoelectrofocusing 
It was performed on G-75 (superfine) Sephadex 
gel from Pharmacia in a Desaga (FRG) apparatus 
with a LKB (Sweden) power delivery system and 
LKB ampholytes pH 3-10 according to [13]. 
2.8. Peptides 
Porcine pancreatic glucagon (highly purified 
grade) from the Novo Res. Inst. (Copenhagen) was 
used without further purification for standard so- 
lutions and was repurified by HPLC followed by 
lyophilization before iodination. 
2.9. Chemicals 
CF3COOH (TFA) was spectroscopic grade 
(Uvasol, Merck, Darmstadt) for the purification 
step. Sequence grade TFA from Pierce (USA) in 
1 g ampules was used for the desalting step. Car- 
rier-free Na125I (IMS 300) for iodination was from 
Amersham (England). Diethylamine 'analyzed re- 
agent' was from Baker (Netherlands)• Acetonitrile 
(CN3CN) was spectroscopic grade (Uvasol), or pro 
analysi grade from Merck. All other chemicals 
were pro analysi grade• Water was purified by run- 
ning tap water into mixed bed resins followed by a 
Milli-Q system (Millipore, USA). 
3. RESULTS 
3.1. Preparation of the starting material 
The concentration of bioactive enteroglucagon 
(fig.l) measured according to its glucagon-like 
effect in rat liver is low in porcine duodenum 
(-0.45/.tg/kg ut; i.e., 0.13nmol/kg ut*), in- 
creases in the first meters of jejunum and fluctu- 
ates between 1.5-3/~g (0.43-0.86 nmol*)/kg gut 
along jejuno-ileum. However, there are no gross 
differences between the concentrations of the pep- 
tide in the first half and in the second half of por- 
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Fig.l. Concentration of bioactive nteroglucagon as 
measured by interaction with glucagon-receptors in at 
liver membranes [4], as a function of the porcine small 
intestinal segment. Conditions for extraction and assay 
are indicated insection 2. 
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Fig.2. Analysis of crude extract of porcine jejuno-ileum 
(see section 3) by isoelectrofocusing on Sephadex gel 
[13]. The glucagon-like binding activity was measured in
samples of the focusing gel at the end of the focusing 
experiment. Details may be found in section 2 and the 
references. 
cine jejuno-ileum (2.35 ~g or 0.67 nmol*/kg vs 
2.1/.tg or 0.6 nmol*/kg). Accordingly and so as to 
simplify collection on a large scale of the desirable 
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Fig.3. Gel filtration of crude porcine jejuno-ileum ex- 
tract (salt-cake) [10] on a Sephadex G-25 (fine) l0 x 
100cm column: load, 17 g salt-cake in 170 ml 0.2 M 
CH3COOH; flowrate, 2.9 l/h, 100 ml-fractions. The 
fraction indicated by the bar was pooled, lyophilized 
and used for further processing. 
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Fig.4. Gel filtration of the G-25 pool (fig.3) on a Bio- 
Gel P6 (100-200 mesh) 5 × 100 cm column: load, 2 g 
lyophilized powder in 30 ml 0.2 M CH3COOH; flowrate 
350 ml/h; pool A contained the bulk of VIP (see section 
3), pool B was lyophilized and used for further 
processing. 
part of intestine, the last 4 -8  m (depending on the 
batch) of porcine jejuno-ileum were collected in a 
slaughter-house as soon as possible after the death 
of the animals and treated as in [10]. Briefly, gut 
was rinsed with tap water, boiled in water for 
l0 min, frozen, minced and extracted in 0.5 M 
CHaCOOH. The extracted peptides were adsorbed 
on alginic acid, eluted with 0.2 M HC1 and precipi- 
tated with NaCl at saturation. The sequence of ad- 
sorption, elution and precipitation was repeated 
once. For analytical purpose, a small portion of 
this precipitate was desalted by gel filtration and 
run on flat bed isoelectrofocusing [13]. The appar- 
ent isoelectric point of bioactive enteroglucagon 
was >9 (fig.2). This indicates that, in agreement 
with its determined structure [6], this peptide is 
much more basic than pancreatic glucagon (iso- 
electric point - 6.5). 
3.2. Isolation procedure 
The peptide precipitate was subjected to gel ill- 
* On a molar basis, the actual concentrations are -5-  
times higher, owing to the lower affinity of bioactive n- 
teroglucagon vs pancreatic glucagon for the hepatic 
glucagon-receptor [4] 
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Fig.5. Cation exchange chromatography of pool B from 
Bio-Gel P6 (fig.4) on a CM-Sepharose 1.5 x 30 cm col- 
umn. Details are given in sections 2 and 3: flowrate 
77 ml/h, 6 ml fractions. Fractions 90-105 were pooled, 
desalted by gel filtration (section 2), lyophilized and 
used for further processing. 
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Fig.6. Gel filtration of the 90-105 pool from CM- 
Sepharose (fig.5) on a Sephadex G-25 (fine) 1 x 200 cm 
column: load, 40 mg lyophilized powder in 1 ml 0.2 M 
CH3COOH, 2.5 ml fractions; flowrate, maintained at 
16 ml/h by use of a peristaltic pump. The pool indicated 
by the bar was lyophilized and used for further 
processing. 
tration on Sephadex G-25 (fig.3). The fraction in- 
dicated by the bar contained all the activity corre- 
sponding to bioactive enteroglucagon. This holds 
true for the other peptides of  the family: secretin 
114], vasoactive intestinal peptide (VIP) [11] and 
porcine intestinal peptide having N-terminal his- 
tidine and C-terminal isoleucine amide (PHI) [15]. 
After lyophilization, this fraction was further pu- 
rified by gel filtration on Bio-Gel P6 (rig.4). The 
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Fig.7. High-performance liquid chromatography 
(HPLC) of the pool from the G-25 column (fig.6) . The 
column-solvent system was that in [12]. Details are 
given in section 2. The separation was obtained under 
the following conditions: flowrate 1.5 ml/min; isocratic 
at 32% CH3CN in 1% TFA/Diethylamine (pH 2.5): de- 
tection at both 220nm (0.2UAFS) and 280nm 
(0.02 UAFS). The peak indicated by the bar was evapo- 
rated in vacuo and injected onto the desalting 
column (fig.8), 
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Fig.8. HPLC of the peak obtained as shown in fig.7. 
Conditions (section 2): column ~tCN 0.4 x 30 cm (Wa- 
ters Assoc.); aqueous olvent 0.13% (w/w) TFA; organic 
solvent, CH3CN containing 0.05% CH3COOCzHs, 
1.5 ml/min- linear gradient from 10-40% organic for 
30min. Detection at 215 mm 0.4AUFS. The peak at 
3 min represented the diethylamine trifluoroacetic salt 
from the preceding column (fig.7). The peak at 12 rain, 
absent when spectroscopic grade CH3CN was used for 
the isolation step (fig.7), represents a UV-absorbing im- 
purity present in pro analysi grade CH3CN. The peak at 
29 rain indicated by a star in the salt-free pure peptide 
that was lyophilized for characterization f its biological 
and chemical features [6]. 
most retarded fraction (B) contained bioactive n- 
teroglucagon, whereas the bulk of VIP was present 
in fraction A (rigA). 
After lyophilization, fraction B was chromato- 
graphed on a cation-exchange column eluted 
with a linear gradient of ionic strength (fig.5). 
Pools of the fractions were desalted by gel filtra- 
tion. The activity eluted as 2 discrete peaks. The 
first one, the nature of which is unknown, was con- 
stantly observed in the numerous column runs. 
The bulk of the activity eluted in front of VIP 
(fig.5). On the basis of its glucagon-like immunore- 
activity (GLI) content, as measured with an anti- 
body that recognizes similarly the glucagon-related 
peptides of either pancreatic or intestinal origin, 
this peak was -20% as potent as pancreatic gluc- 
agon on the binding of 125I-glucagon to its hepatic 
Table 1 
Purification factors and yields obtained at each step of 
the isolation procedure 
Step Factor Yield 
G-25 6 60% 
P-6 5 50% 
CM 15 50% 
G-25 5 60% 
H PLC- 1 40 80% 
HPLC-2 - 100% 
Total 90 000 7% 
Purification factors were calculated from the increase in 
specific activity of the lyophilized powders as measured 
by the binding assay. The yields were calculated from 
the total activity recovered divided by that recovered in
the preceding step 
receptors and -10% as potent as pancreatic 
glucagon in stimulating hepatic adenylate cyclase. 
These characteristics are those of the peptide sus- 
pected to be present in the crude extracts [3,4,16] 
and which were chosen as the criteria for following 
up the purification procedure. Accordingly, this 
fraction was selected for further processing. 
After another gel filtration step (fig.6), the pep- 
tide was isolated by HPLC (fig.7) using the col- 
umn-solvent system developed in [12]. This step 
allowed, with a 40-fold purification factor, separa- 
tion of bioactive enteroglucagon from the foreign 
peptidic material (fig.7). Another HPLC run using 
completely volatile solvents (fig.8) yielded, after 
lyophilization, the peptide in a salt-free pure form. 
Table I summarizes the different steps of puri- 
fication; with an overall yield of -7%, one ton 
(boiled wet wt) of porcine jejuno-ileum yielded 
0.5 mg pure peptide. 
4. DISCUSSION 
In 1948, Sutherland et al. [1] observed that, sim- 
ilarly to pancreatic glucagon, intestinal extracts 
were able to activate the hepatic adenylate cyclase. 
However, they did not further characterize the ma- 
terial showing this activity. On the other hand, the 
development by Unger's group of the glucagon ra- 
dioimmunoassay llowed investigation of the GLI 
present in different issues from several species. Of 
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particular interest was the study by Valverde et al. 
[2] on the characterization f GLI in dog intestine: 
on gel filtration, mainly 2 peaks of GLI were 
found, a prominent one of relatively high Mr 
(8000-9000) and a smaller one, eluting not far 
from pancreatic glucagon. In 1973-1974 [3,4] we 
showed, using the methods developed for the study 
of glucagon-receptors [17], that the small, low-Mr 
second peak contained a molecule that was able to 
bind to the hepatic glucagon-receptor and to acti- 
vate, presumably through this receptor, hepatic ad- 
enylate cyclase. Using these in vitro characteristics 
for screening the fractions during the purification 
procedure, we succeeded in isolating the peptide 
responsible for these activities. 
If we disregard the minor peak observed uring 
the ion-exchange chromatography (fig.5) which 
may represent a degraded (e.g., deamidated) form 
of the active peptide, a single peak of activity on 
hepatic receptors has been observed all along the 
purification. This homogeneity leads us to con- 
clude that the peptide that we have isolated is the 
main, if not the single, biologically active peptide 
present in porcine intestine that interacts with the 
glucagon-sensitive hepatic system. Accordingly, 
this peptide is likely to represent the intestinal hy- 
perglycemic-glycogenolytic factor discovered in 
[!]; the term 'bioactive enteroglucagon' appears 
thus to be convenient. On the other hand, the term 
'oxyntomodulin' describes in a more adequate way 
the peptide in terms of biological activity since its 
main action appears to be at the level of the acid- 
secreting oxyntic glands of stomach [5] rather than 
at the hepatic level; 'glucagon-37' is related to its 
chemical structure [6]. 
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